Green H J, Pakenham K I, Headley B C, Yaxley J, Nicol D L, Mactaggart P N, Swanson C, Watson R B, Gardiner R A
School of Psychology and Department of Surgery, The University of Queensland, Queensland, Australia.
BJU Int. 2002 Sep;90(4):427-32. doi: 10.1046/j.1464-410x.2002.02917.x.
To report the first systematic investigation of the cognitive effects of luteinizing hormone-releasing hormone (LHRH) analogues in male patients, as LHRH analogues have been associated with memory impairments in women using these drugs for gynaecological conditions.
Eighty-two men with extraprostatic prostate cancer were randomly assigned to receive either continuous leuprorelin, goserelin (both LHRH analogues), cyproterone acetate (a steroidal antiandrogen) or close clinical monitoring. These patients underwent cognitive assessments at baseline and before starting treatment (77), and then 6 months later (65).
Compared with the baseline assessments, men receiving androgen suppression monotherapy performed worse in two of 12 tests of attention and memory; 24 of 50 men randomized to active treatment and assessed 6 months later had a clinically significant decline in one or more cognitive tests but not one patient randomized to close monitoring showed a decline in any test performance.
Pharmacological androgen suppression monotherapy for prostate cancer may be associated with impaired memory, attention and executive functions.
报告对男性患者促黄体生成激素释放激素（LHRH）类似物认知效应的首次系统性研究，因为LHRH类似物与使用这些药物治疗妇科疾病的女性的记忆障碍有关。
82例前列腺外前列腺癌男性患者被随机分配接受持续亮丙瑞林、戈舍瑞林（均为LHRH类似物）、醋酸环丙孕酮（一种甾体类抗雄激素药物）或密切临床监测。这些患者在基线时、开始治疗前（77例）以及6个月后（65例）接受了认知评估。
与基线评估相比，接受雄激素抑制单一疗法的男性在12项注意力和记忆测试中的2项表现较差；随机分配接受积极治疗并在6个月后接受评估的50名男性中有24名在一项或多项认知测试中出现了具有临床意义的下降，但随机分配接受密切监测的患者中没有一人在任何测试表现中出现下降。
前列腺癌的药物性雄激素抑制单一疗法可能与记忆、注意力和执行功能受损有关。
